What is the recommended first‑line treatment and relapse‑prevention strategy for an acute MOG‑antibody disease attack in a child?

Treatment of Acute MOG-Antibody Disease in Children

For acute MOG-antibody disease attacks in children, initiate high-dose intravenous corticosteroids (methylprednisolone) as first-line therapy, followed by a prolonged steroid taper of at least 6 months to prevent relapses, with IVIG as a particularly effective option especially in pediatric patients. 1

Acute Attack Management

First-Line Treatment

• Intravenous methylprednisolone (IVMP) is the standard acute therapy
• If inadequate response to IVMP, escalate to plasma exchange or immunoadsorption - MOG-positive patients show particularly good responses to antibody-depleting treatments 1
• Intravenous immunoglobulin (IVIG) is especially effective in children with MOGAD 1

Critical Steroid Tapering Strategy

MOG-EM carries a high risk of flare-ups after cessation of steroid treatment - this is a key distinguishing feature from MS 1. The evidence strongly supports:

• Prolonged oral corticosteroid taper extending at least 6 months during remission
• Recent pediatric data shows patients receiving oral corticosteroids ≥6 months had significantly lower relapse rates (42.4% vs 65.3%, p=0.026) 2
• Abrupt steroid discontinuation frequently triggers relapses 1

Relapse Prevention Strategy

Risk Stratification for Long-Term Therapy

Identify high-risk children who need maintenance immunotherapy:

High-risk features predicting relapse:

• Seizures at onset (OR 7.155) 2
• Limb weakness at onset (OR 5.157) 2
• High serum MOG antibody titers (≥1:100) 2
• Elevated CSF cell counts (>30 × 10⁶/L) 2
• Persistent MOG antibody positivity at 3 months 3

Protective factor:

• Normal brain MRI (OR 0.186) 2

Long-Term Immunotherapy Options

For children with relapsing disease or high-risk features:

1. Monthly IVIG: Effective maintenance therapy with favorable safety profile in children 3. A 6-month limited course of early IVIG may reduce multiphasic disease risk 4

2. Mycophenolate mofetil: Achieves disease control in relapsing cases 5

3. Rituximab: B cell-targeted therapy effective for long-term management 1

4. Immunosuppressive treatments: General category showing efficacy 1

Monitoring Strategy

MOG Antibody Titer Monitoring

• Re-test MOG-IgG at 3 months post-attack - seronegativity at this timepoint suggests monophasic disease 3
• However, titers at 6 months can be inconsistent 3
• Some patients with relapsing disease show transient seronegativity 1
• Do not base long-term treatment decisions solely on antibody disappearance - intervals between attacks can span years 1

Clinical Monitoring

• Close surveillance during steroid taper
• Watch for early relapse signs, particularly in high-risk patients
• Consider MOG-Ab titer-guided steroid tapering in select cases 6

Key Clinical Pitfalls

1. Avoid abrupt steroid cessation - this is the most common trigger for relapses in MOG-EM 1

2. Do not use MS disease-modifying therapies - interferon-beta and natalizumab may be ineffective or harmful in MOG-EM due to different immunopathogenesis 1

3. Recognize phenotype evolution - ADEM is most common at onset (38.9%), but optic neuritis becomes predominant at relapse (48.9%) 2

4. Distinguish from MS - MOG-EM lacks Dawson's fingers, ovoid periventricular lesions, and CSF-restricted oligoclonal bands 1

Treatment Algorithm Summary

Acute attack → IVMP → (if inadequate response) → Plasma exchange/IVIG
↓
Prolonged steroid taper (≥6 months)
↓
Assess relapse risk (seizures, limb weakness, high titers, abnormal brain MRI)
↓
High risk → Maintenance therapy (monthly IVIG or immunosuppressant)
Low risk → Monitor closely, re-test MOG-IgG at 3 months

The relapse rate in pediatric MOGAD is approximately 30.6% 2, making careful risk stratification and appropriate maintenance therapy essential for optimizing long-term outcomes.